Sarepta Therapeutics, Inc. (SRPT)

Sarepta Therapeutics' stock price has been volatile. Key events include the FDA's decision regarding Elevidys shipments, a restructuring involving job cuts, Q1 2025 financial results showing revenue growth but lowered guidance, Q3 2025 results impacted by lower Elevidys shipments, and positive EMBARK study results.

The provided information does not explicitly indicate demand seasonality for Sarepta Therapeutics' products and services. However, the company has shown strong and accelerating revenue growth, particularly for Elevidys.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare neuromuscular diseases, particularly Duchenne muscular dystrophy (DMD). The company develops RNA-targeted and gene therapies, with FDA-approved products like Exondys 51, Vyondys 53, Amondys 45, and Elevidys. Sarepta has a pipeline of over 40 programs targeting other genetic muscle disorders.

Sarepta Therapeutics is headquartered in Cambridge, Massachusetts, with commercial operations in North America and collaborations in Europe and Asia. The company also has offices in Ireland and Switzerland, reflecting its global presence.

Sarepta Therapeutics' brand reputation has been affected by safety concerns and label changes related to Elevidys, including patient deaths and subsequent layoffs. The FDA's decision to remove a pause on Elevidys shipments and positive clinical trial results from the EMBARK study have positively influenced the company's reputation.

Sarepta Therapeutics has significant institutional ownership, with 622 institutional owners holding 71.65% of the company's shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, and State Street Corp. Individuals hold 5.22% of the company.